Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Standard BioTools Inc. (NASDAQ:LAB – Free Report) by 184.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 50,330 shares of the company’s stock after purchasing an additional 32,640 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Standard BioTools were worth $89,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Freestone Capital Holdings LLC acquired a new stake in shares of Standard BioTools during the 1st quarter worth $31,000. Evolution Wealth Advisors LLC acquired a new stake in shares of Standard BioTools during the 1st quarter worth $33,000. Shell Asset Management Co. acquired a new stake in shares of Standard BioTools during the 1st quarter worth $39,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of Standard BioTools during the 2nd quarter worth $39,000. Finally, Peak Asset Management LLC acquired a new stake in Standard BioTools in the 1st quarter valued at $46,000. 53.74% of the stock is currently owned by institutional investors and hedge funds.
Standard BioTools Trading Up 0.5 %
Shares of NASDAQ LAB opened at $2.00 on Wednesday. Standard BioTools Inc. has a 12-month low of $1.21 and a 12-month high of $3.05. The company has a market cap of $742.30 million, a P/E ratio of -1.98 and a beta of 1.58. The stock has a fifty day moving average price of $1.96 and a 200 day moving average price of $2.29.
Analyst Ratings Changes
Separately, TD Cowen lowered their price target on Standard BioTools from $3.50 to $2.75 and set a “buy” rating for the company in a report on Thursday, August 1st.
Read Our Latest Analysis on Standard BioTools
Insider Activity
In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 200,000 shares of the stock in a transaction dated Monday, August 5th. The stock was bought at an average cost of $1.58 per share, for a total transaction of $316,000.00. Following the completion of the purchase, the director now directly owns 47,930,821 shares of the company’s stock, valued at $75,730,697.18. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders acquired 5,117,508 shares of company stock worth $8,662,080 over the last ninety days. Corporate insiders own 53.10% of the company’s stock.
Standard BioTools Company Profile
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
- Five stocks we like better than Standard BioTools
- What is the NASDAQ Stock Exchange?
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- 3 Fintech Stocks With Good 2021 Prospects
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Want to see what other hedge funds are holding LAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Standard BioTools Inc. (NASDAQ:LAB – Free Report).
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.